vs
LANDMARK BANCORP INC（LARK）与REGENXBIO Inc.（RGNX）财务数据对比。点击上方公司名可切换其他公司
REGENXBIO Inc.的季度营收约是LANDMARK BANCORP INC的1.6倍（$30.3M vs $18.8M），LANDMARK BANCORP INC净利率更高（27.0% vs -221.3%，领先248.3%），REGENXBIO Inc.同比增速更快（43.0% vs 14.0%），过去两年REGENXBIO Inc.的营收复合增速更高（39.4% vs 13.1%）
Landmark Bancorp Inc是一家总部位于美国的银行控股公司，运营Landmark National Bank，主要服务美国堪萨斯州的社区客户，提供全方位个人及商业银行服务，包括存款账户、住房抵押贷款、商业贷款及财富管理方案，服务对象涵盖个人消费者与本地中小企业。
REGENXBIO Inc.是一家临床阶段生物技术企业，专注于开发针对罕见及严重遗传疾病的突破性基因疗法。公司拥有专有的腺相关病毒载体技术，既向全球生物制药合作伙伴提供技术授权，也自主推进多疾病领域的基因疗法管线研发。
LARK vs RGNX — 直观对比
营收规模更大
RGNX
是对方的1.6倍
$18.8M
营收增速更快
RGNX
高出29.0%
14.0%
净利率更高
LARK
高出248.3%
-221.3%
两年增速更快
RGNX
近两年复合增速
13.1%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $18.8M | $30.3M |
| 净利润 | $5.1M | $-67.1M |
| 毛利率 | — | — |
| 营业利润率 | — | -190.0% |
| 净利率 | 27.0% | -221.3% |
| 营收同比 | 14.0% | 43.0% |
| 净利润同比 | 7.8% | -31.2% |
| 每股收益（稀释后） | — | $-1.30 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收LARKRGNX
| Q1 26 | $18.8M | — | ||
| Q4 25 | $18.7M | $30.3M | ||
| Q3 25 | $18.2M | $29.7M | ||
| Q2 25 | $17.3M | $21.4M | ||
| Q1 25 | $16.5M | $89.0M | ||
| Q4 24 | $15.8M | $21.2M | ||
| Q3 24 | $15.9M | $24.2M | ||
| Q2 24 | $14.7M | $22.3M |
净利润LARKRGNX
| Q1 26 | $5.1M | — | ||
| Q4 25 | $4.7M | $-67.1M | ||
| Q3 25 | $4.9M | $-61.9M | ||
| Q2 25 | $4.4M | $-70.9M | ||
| Q1 25 | $4.7M | $6.1M | ||
| Q4 24 | $3.3M | $-51.2M | ||
| Q3 24 | $3.9M | $-59.6M | ||
| Q2 24 | $3.0M | $-53.0M |
毛利率LARKRGNX
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 70.2% | ||
| Q3 24 | — | 48.8% | ||
| Q2 24 | — | 52.5% |
营业利润率LARKRGNX
| Q1 26 | — | — | ||
| Q4 25 | 31.7% | -190.0% | ||
| Q3 25 | 33.4% | -176.3% | ||
| Q2 25 | 30.9% | -296.3% | ||
| Q1 25 | 34.7% | 13.6% | ||
| Q4 24 | 15.2% | -242.1% | ||
| Q3 24 | 30.3% | -256.6% | ||
| Q2 24 | 24.5% | -251.3% |
净利率LARKRGNX
| Q1 26 | 27.0% | — | ||
| Q4 25 | 32.1% | -221.3% | ||
| Q3 25 | 27.1% | -208.3% | ||
| Q2 25 | 25.4% | -331.8% | ||
| Q1 25 | 28.5% | 6.8% | ||
| Q4 24 | 26.5% | -241.3% | ||
| Q3 24 | 24.8% | -246.3% | ||
| Q2 24 | 20.5% | -237.7% |
每股收益（稀释后）LARKRGNX
| Q1 26 | — | — | ||
| Q4 25 | $0.66 | $-1.30 | ||
| Q3 25 | $0.85 | $-1.20 | ||
| Q2 25 | $0.75 | $-1.38 | ||
| Q1 25 | $0.81 | $0.12 | ||
| Q4 24 | $0.47 | $-0.99 | ||
| Q3 24 | $0.68 | $-1.17 | ||
| Q2 24 | $0.52 | $-1.05 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $31.9M | $230.1M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | — | $102.7M |
| 总资产 | $1.6B | $453.0M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资LARKRGNX
| Q1 26 | $31.9M | — | ||
| Q4 25 | — | $230.1M | ||
| Q3 25 | — | $274.2M | ||
| Q2 25 | — | $323.3M | ||
| Q1 25 | — | $267.9M | ||
| Q4 24 | — | $234.7M | ||
| Q3 24 | — | $255.5M | ||
| Q2 24 | — | $290.4M |
股东权益LARKRGNX
| Q1 26 | — | — | ||
| Q4 25 | $160.6M | $102.7M | ||
| Q3 25 | $155.7M | $161.5M | ||
| Q2 25 | $148.4M | $213.7M | ||
| Q1 25 | $142.7M | $274.2M | ||
| Q4 24 | $136.2M | $259.7M | ||
| Q3 24 | $139.7M | $301.4M | ||
| Q2 24 | $128.3M | $348.3M |
总资产LARKRGNX
| Q1 26 | $1.6B | — | ||
| Q4 25 | $1.6B | $453.0M | ||
| Q3 25 | $1.6B | $525.2M | ||
| Q2 25 | $1.6B | $581.0M | ||
| Q1 25 | $1.6B | $490.9M | ||
| Q4 24 | $1.6B | $466.0M | ||
| Q3 24 | $1.6B | $519.1M | ||
| Q2 24 | $1.6B | $569.4M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $-52.3M |
| 自由现金流经营现金流 - 资本支出 | — | $-52.8M |
| 自由现金流率自由现金流/营收 | — | -174.0% |
| 资本支出强度资本支出/营收 | — | 1.7% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $-126.4M |
8季度趋势，按日历期对齐
经营现金流LARKRGNX
| Q1 26 | — | — | ||
| Q4 25 | $21.6M | $-52.3M | ||
| Q3 25 | $10.3M | $-56.0M | ||
| Q2 25 | $439.0K | $-49.3M | ||
| Q1 25 | $8.0M | $33.6M | ||
| Q4 24 | $14.2M | $-31.6M | ||
| Q3 24 | $8.1M | $-40.5M | ||
| Q2 24 | $4.4M | $-45.5M |
自由现金流LARKRGNX
| Q1 26 | — | — | ||
| Q4 25 | $21.0M | $-52.8M | ||
| Q3 25 | $10.1M | $-56.5M | ||
| Q2 25 | $354.0K | $-49.7M | ||
| Q1 25 | $8.0M | $32.6M | ||
| Q4 24 | $11.9M | $-32.7M | ||
| Q3 24 | $7.8M | $-40.9M | ||
| Q2 24 | $3.8M | $-46.0M |
自由现金流率LARKRGNX
| Q1 26 | — | — | ||
| Q4 25 | 112.5% | -174.0% | ||
| Q3 25 | 55.4% | -189.9% | ||
| Q2 25 | 2.0% | -232.8% | ||
| Q1 25 | 48.4% | 36.6% | ||
| Q4 24 | 75.6% | -154.2% | ||
| Q3 24 | 49.3% | -168.9% | ||
| Q2 24 | 25.6% | -206.2% |
资本支出强度LARKRGNX
| Q1 26 | — | — | ||
| Q4 25 | 3.2% | 1.7% | ||
| Q3 25 | 1.4% | 1.7% | ||
| Q2 25 | 0.5% | 1.8% | ||
| Q1 25 | 0.3% | 1.2% | ||
| Q4 24 | 14.7% | 5.1% | ||
| Q3 24 | 1.8% | 1.3% | ||
| Q2 24 | 4.2% | 2.1% |
现金转化率LARKRGNX
| Q1 26 | — | — | ||
| Q4 25 | 4.56× | — | ||
| Q3 25 | 2.09× | — | ||
| Q2 25 | 0.10× | — | ||
| Q1 25 | 1.71× | 5.53× | ||
| Q4 24 | 4.34× | — | ||
| Q3 24 | 2.06× | — | ||
| Q2 24 | 1.45× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
LARK
暂无分部数据
RGNX
| Novartis Gene Therapies | $24.2M | 80% |
| Nippon Shinyaku Collaboration And License Agreement | $4.3M | 14% |
| Nippon Shinyaku Services | $1.4M | 5% |
